The un-audited standalone financial results along with limited review report for the quarter and nine months ending December 31, 2025, as approved by Board of Directors in their meeting ....
Awaiting price reaction for this filing.
Dharti Proteins (formerly Devika Proteins) reported near-zero revenue of Rs. 0.44 lakh in Q3 FY26 against expenses of Rs. 81.82 lakh, resulting in a loss after tax of Rs. 34.22 lakh (EPS of negative Rs. 0.33). For the nine months ended December 2025, total revenue was just Rs. 2.93 lakh with a cumulative loss of Rs. 35.24 lakh. The statutory auditor issued a Qualified Opinion flagging going concern doubts, non-compliance with MSMED Act, likely bad debts of Rs. 150.46 lakh in loans and advances, and unverifiable other current assets/liabilities. The company's net worth is deeply negative at Rs. (146.42) lakh against total assets of Rs. 232.53 lakh and liabilities of Rs. 378.95 lakh, and it has not paid BSE listing fees. The filing is made in the context of an approved resolution plan under CIRP (NCLT order dated November 18, 2025).
Extremely negative for existing public shareholders: the approved resolution plan slashes public shareholding to just 25,000 equity shares (massive dilution from 1.02 crore shares), with 4,75,000 fresh shares going to the resolution applicant and financial creditors. The stock is effectively a non-operational, insolvent shell — avoid unless you fully understand the restructuring outcome.